Table 2.
Baseline Characteristics of RED-ROSE cohort
| WORST REPORTED SYMPTOM | ||||
|---|---|---|---|---|
| Characteristic | All (N=232) |
Dyspnea (N=141) |
Fatigue (N=24) |
Body Swelling (N=67) |
| Age, years | 69 (62–79) | 68 (60–75) | 71 (62–82) | 72 (62–82) |
| Male sex | 159 (69%) | 96 (68%) | 17 (71%) | 46 (69%) |
| White race | 166 (72%) | 98 (70%) | 18 (75%) | 50 (75%) |
| HF hospitalization | 143 (62%) | 93 (67%) | 13 (54%)* | 37 (55%)* |
| Ejection fraction, % | 35 (23–54) | 33 (23–52) | 43 (18–55) | 38 (23–53) |
| Ejection fraction ≥ 50% | 76 (33%) | 42 (30%) | 10 (42%) | 24 (36%) |
| Hypertension | 195 (84%) | 120 (85%) | 19 (79%) | 56 (84%) |
| Diabetes | 127 (55%) | 80 (57%) | 14 (58%) | 33 (49%) |
| Stroke | 21 (9%) | 10 (7%) | 4 (17%) | 7 (10%) |
| Atrial fibrillation | 135 (58%) | 74 (52%) | 18 (75%)* | 43 (64%) |
| COPD | 59 (25%) | 41 (29%) | 3 (13%) | 15 (22%) |
| Medications | ||||
| Loop diuretic | 215 (93%) | 128 (91%) | 24 (100%) | 63 (94%) |
| ACE or ARB | 112 (48%) | 74 (52%) | 6 (25%)* | 32 (48%) |
| Hydralazine | 52 (22%) | 30 (21%) | 6 (25%) | 16 (24%) |
| Nitrates | 60 (26%) | 39 (28%) | 5 (21%) | 16 (24%) |
| Beta blocker | 196 (84%) | 120 (85%) | 22 (92%) | 54 (81%) |
| Aldosterone antagonist | 68 (29%) | 44 (31%) | 6 (25%) | 18 (27%) |
| Digoxin | 53 (23%) | 29 (21%) | 8 (33%) | 16 (24%) |
| Clinical Examination | ||||
| Heart rate (bpm) | 74 (66–85) | 76 (68–85) | 72 (66–81) | 71 (63–85) |
| Systolic BP, mmHg | 116 (104–129) | 117 (106–127) | 114 (106–124) | 114 (100–132) |
| Body mass index, Kg/m2 | 31 (27–37) | 31 (28–37) | 29 (25–37) | 31 (27–37) |
| JVP ≥ 8 cm, (n=224) | 212 (95%) | 125 (93%) | 24 (100%) | 63 (97%) |
| Rales (n=227) | 122 (54%) | 81 (59%) | 12 (52%) | 29 (46%)* |
| Edema ≥ 2+/4+ (n=229) | 159 (69%) | 89 (64%) | 18 (75%) | 52 (79%)* |
| Orthopnea, (n=219) | 193 (88%) | 126 (95%) | 20 (87%)* | 47 (75%)* |
| Laboratory data | ||||
| Hemoglobin, g/dL | 11.5 (10.4–12.8) | 11.8 (10.4–12.9) | 11.4 (10.7–12.6) | 11.2 (10.3–12.6) |
| eGFR, mL/min/1.73m2 | 45 (33–56) | 45 (35–57) | 48 (33–57) | 42 (30–51)* |
| NT Pro-BNP, pg/mL | 5055 (2358–10348) | 5109 (2371–9516) | 4269 (2223–12402) | 5268 (2905–11888) |
| Baseline Symptom Scores | ||||
| Dyspnea VAS | 62.5 (40.0–82.0) | 54.0 (35.0–75.0) | 77.0 (54.0–92.0)* | 74.5 (50.0–90.0)* |
| WS-VAS | 50.0 (25.0–71.0) | 54.0 (35.0–75.0) | 52.0 (47.0–80.0) | 32.5 (18.0–56.0)*† |
Data are number (%) or median (interquartile range).
*
p<0.05 vs dyspnea as worse symptom,
†
p <0.05 vs fatigue as worst symptom for “Baseline Symptom Scores” analysis only.
Abbreviations:
ACE, Angiotensin Converting Enzyme; ARB, Angiotensin Receptor Blocker; BP, Blood Pressure; COPD, Chronic Obstructive Pulmonary Disease; eGFR, Estimated Glomerular Filtration Rate; HF, Heart Failure; JVP, Jugular Venous Pressure; NT Pro-BNP, N-terminal pro-brain natriuretic peptide